US FDA approves Ipsen's SohonosTM (palovarotene) capsules,
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia...
Source: globenewswire.com
Page 2 - Sponsored Level News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sponsored Level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sponsored Level Today - Breaking & Trending Today
US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia ossificans progressiva FOP impacts about 400... -Today at 03:33 pm- MarketScreener
Source: marketscreener.com
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
Paris, France: 27 July 2023Ipsen , a global specialty-care biopharmaceutical company, presents today its financial results for the first half of 2023. H1 2023 total sales up by 7.4% at CER1 , with...
Source: marketscreener.com
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use based on Bylvay Phase III ASSERT clinical-trial data in Alagille syndrome Negative opinion from Committee for Orphan Medicinal...
Source: marketscreener.com
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use based on Bylvay Phase III ASSERT clinical-trial data in Alagille syndrome Negative opinion from Committee for Orphan Medicinal...
Source: marketscreener.com